

**IN THE CLAIMS:**

Please cancel claims 24 and 52 without prejudice or disclaimer and amend claims 15, 22, 25-29, and 33-34 as follows:

*Sub C'*  
~~15. (Twice Amended) An antibody which binds to a nuclear matrix protein, or a fragment thereof, selected from the group consisting of:~~

*Sub C'*  
~~(a) RCCA-1 having a molecular weight of about 53 kD and a pI of about 9.30;~~  
~~(b) RCCA-2 having a molecular weight of about 32 kD and a pI of about 6.95;~~  
~~(c) RCCA-3 having a molecular weight of about 27 kD and a pI of about 6.50;~~  
~~(d) RCCA-4 having a molecular weight of about 20 kD and a pI of about 5.25;~~  
~~(e) RCCA-5 having a molecular weight of about 15 kD and a pI of about 6.00; and~~

*Sub C'*  
~~(f) RCNL-1 having a molecular weight of about 103 kD and a pI of about 8.30, said nuclear matrix protein is present in normal renal cells but absent in cancerous renal cells, or absent in normal renal cells but present in cancerous renal cells.~~

*Sub C'*  
~~22. (Twice amended) A method for detecting a cell proliferative disorder in a subject, comprising contacting a cellular component from the subject with said antibody of claim 15, which binds to a cellular component associated with a cell proliferative disorder, and detecting whether or not the antibody binds to the cellular component.~~

*Sub C'*  
25. (Amended) The method of claim 22, wherein said antibody is polyclonal.

26. (Amended) The method of claim 22, wherein said antibody is monoclonal.

*Sub C'*  
27. (Amended) The method of claim 22, wherein said antibody is detectably labeled.

28. (Amended) The method of claim 27, wherein said label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, and an enzyme.

*BS*

29. (Amended) A method of treating a cell proliferative disorder associated with a renal matrix protein selected from the group consisting of RCCA-1, RCCA-2, RCCA-3, RCCA-4, RCCA-5, RCNL-1, comprising administering to a subject with said disorder a therapeutically effective amount of said antibody of claim 15, which blocks or enhances the function of said renal matrix protein.

---

*BS*

33. (Amended) The method of claim 29, wherein said antibody is monoclonal.

34. (Amended) The method of claim 29, wherein said antibody is polyclonal.

---

In addition, please add the following new claims:

*B6*

48. (New) The method of claim 22, wherein said cellular component is taken from the subject's kidney.

*B6*

49. (New) The method of claim 22, wherein said cellular component is a protein.

---